Chang Guang (6730-TW), a manufacturer of minimally invasive surgical instruments, achieved a revenue of 4.88 billion NT dollars in 2025, setting a new historical high. On the 23rd, Chang Guang pointed out that with the blooming of overseas markets, the growth momentum in Europe and the Middle East is strong, the Chinese market is riding the trend of robotic surgery, and the U.S. market has smoothly secured orders and begun shipping. The company expects this year's revenue to break records.

Chang Guang stated that in the European market, by introducing bipolar electrosurgical knives, laparoscopic surgery instruments, and integrated product kits, the company has transformed into a comprehensive solution provider. Among these, Greece's performance was particularly outstanding, with Greece's first-half revenue increasing by 28.74% year-on-year, simultaneously boosting Europe's market share.

Regarding the Middle East market, Chang Guang pointed out that Oman has become an important growth engine, benefiting from the local distribution network and the continuous expansion of pediatric surgery applications. Oman's first-half revenue this year increased by 2.46 times year-on-year.

Chang Guang mentioned that the Chinese market is riding the development trend of robotic surgery. By using single-port laparoscopic surgery pathway devices to meet the demand for robotic surgery, the company has driven sales in regions such as Shanghai and Zhejiang. The sales volume of this product in the first half of this year increased by 31.99% year-on-year.

In the U.S. market, Chang Guang's subsidiary's laparoscopic surgery suction tubes and instruments obtained U.S. FDA 510(k) medical device approval in 2025 and successfully secured orders and began shipping this year.

Chang Guang's June revenue was 465.03 million NT dollars, up 11.3% month-on-month and 13.25% year-on-year. The cumulative revenue for the first half of this year was 2.42 billion NT dollars, up 1.98% year-on-year.

FACT BOX

  • Source: PR Times
  • Category: News